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Previewsincreased tumor grade and decreased
patient survival in glioma, suggesting
that increased eEF2K might promote tu-
mor cell survival, perhaps by providing
protection from nutrient deprivation.
While still a poorly defined area of tumor
biology, tumor cells are believed to expe-
rience intermittent availability of specific
nutrients during the course of tumor pro-
gression due to insufficient or aberrant
vasculature feeding the tumor. Therefore,
the observed increase in eEF2K expres-
sion in glioma may be an adaptive
response to fluctuating nutrients in the tu-
mor microenvironment, especially in
advanced tumors. Another question is
whether the tumor microenvironment
ever experiences extreme levels of
nutrient starvation approaching those
levels typically used in cell culture experi-
ments. Interestingly, Leprivier et al. (2013)
demonstrate that xenograft tumors from
cells overexpressing eEF2K, while greatly
reduced in size, are resistant to the
growth inhibitory effects of calorie restric-
tion. Reciprocally, eEF2K null tumors dis-
played increased necrosis and apoptosis
under calorie restriction, whereas their
growth was indistinguishable from wild-
type tumors in mice fed a normal diet.
Therefore, these findings provide another
example whereby tumor cell-intrinsicnutrient-sensing pathways act in concert
with the nutritional status of the host to in-
fluence tumor growth (Kalaany and Saba-
tini, 2009). However, as circulating
glucose levels are only marginally
affected by calorie restriction, this
response is likely to reflect changes in
both local and systemic (insulin and
IGF1) nutrient signals.
Other key questions remain. How does
sustained translation elongation kill
nutrient-deprived cells when translation
initiation is appropriately inhibited? The
signal stimulating cell death must
emanate from a specific form of stress,
or perhaps a selected class of proteins,
produced by sustained translation elon-
gation in the absence of exogenous nutri-
ents. Would pharmacological inhibitors to
eEF2K, alone or in combination with other
compounds, be effective cancer treat-
ments? Intriguingly, reducing eEF2K
expression has been shown to sensitize
glioma cells to the glucose analog 2-de-
oxyglucose (Wu et al., 2009). Whereas
the dependence on eEF2K under
nutrient-deplete conditions is not specific
to tumor cells, it might be particularly
important in the context of the tumor
microenvironment. eEF2K joins a growing
list of adaptive responses to starvation
(including the regulation of AMPK,Cancer CellmTORC1, and autophagy), which, due to
defective control in tumor cells, could
represent a vulnerability and a therapeutic
opportunity.REFERENCES
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The scaffold protein IQGAP1 regulates cell signaling through the RAF/MEK/ERK pathway. Recent data show
that cancer cells in which the RAF/MEK/ERK pathway is activated are particularly sensitive to the disruption
of IQGAP1 function. IQGAP drugs may be particularly effective in tumors that develop resistance to existing
pathway drugs.The receptor tyrosine kinase (RTK)/RAS/
RAF/MEK/ERK pathway drives prolifera-
tion, survival, invasion, and metastasis in
human cancer. Antibodies that bind to
the extracellular domains of RTKs or small
molecule inhibitors that block RTK kinase
activity are effective in a variety of cancersif the patients are appropriately selected.
More recently, it has been shown that
drugs that target BRAF and MEK are
effective in melanoma patients whose tu-
mors carry BRAF mutations (Catalanotti
et al., 2013; Chapman et al., 2011; Falc-
hook et al., 2012; Flaherty et al., 2010,2012; Hauschild et al., 2012). Thus, this
pathway is a validated therapeutic target
in cancer, and its protein kinases, in
particular, have been shown to be trac-
table therapeutic targets.
In contrast to kinases, the RAS small
G-proteins appear to be intractable23, June 10, 2013 ª2013 Elsevier Inc. 715
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Figure 1. IQGAP1 Is a Therapeutic Target in ERK-Pathway-Driven Cancer Cells
(A) IQGAP1 forms a signaling complex with RAF, MEK, and ERK. Mutant RAS (*RAS) or BRAF (*BRAF) hyperactivates ERK signaling and promotes tumor cell
proliferation and survival. Delivery of exogenous WW peptide (WW PEPT) prevents ERK binding to IQGAP1 through its WW domain (WW) and suppresses
ERK activity, thereby blocking proliferation in cancer cells that are addicted to the ERK pathway.
(B) The scaffold function of IQGAP1 within the ERK pathway is dispensable in normal cell differentiation, growth, and survival.
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Previewstherapeutic targets. This is frustrating,
because collectively the RAS genes
(HRAS, KRAS, and NRAS) are the
most commonly mutated oncogenes in
human cancer. Oncogenic RAS thus is
an important but untapped therapeutic
target. One way to resolve this problem
is to target downstream kinases on
the pathway, such as MEK and AKT.
Recently, it was suggested that the scaf-
fold protein IQGAP1 may be another
Achilles’ heel downstream of RAS that
can also be targeted (Jameson et al.,
2013).
Scaffold proteins regulate cell biology
by binding to and organizing the compo-
nents of a signaling pathway into com-
plexes. This improves signaling efficiency
by tethering proteins to each other to in-
crease signal flux between them. It also
improves fidelity by confining signaling
to the proteins within the complexes.
IQGAP1 is a multifunctional scaffold pro-
tein that binds to almost 100 other pro-
teins. Although IQGAP1 has two closely
related family proteins (IQGAP2 and
IQGAP3) that serve distinct functions,716 Cancer Cell 23, June 10, 2013 ª2013 ElsIQGAP1 is the more widely expressed
protein and the only one reported as upre-
gulated in cancer. IQGAP1 is implicated in
cytoskeletal reorganization and regulation
of cell-cell adhesion, polarity, and migra-
tion (Johnson et al., 2009). IQGAP1 also
binds to RAF and MEK through the IQ
domain and to ERK through the proline-
rich WW domain to regulate RAF/MEK/
ERK signaling.
Starting with the premise that IQGAP
regulates tumorigenesis through the
RAF/MEK/ERK pathway, Jameson et al.
(2013) demonstrated that Iqgap null
mice were resistant to Hras-driven chem-
ical carcinogenesis, depletion of IQGAP
reduced in vitro invasion of RAS-driven
cancer cells, and IQGAP1 is highly ex-
pressed in human cutaneous squamous
cell carcinoma. They found that depletion
of IQGAP suppressed ERK activity and
that this could be rescued by IQGAP re-
expression unless the WW domain was
mutated to prevent ERK binding. Further-
more, expression of the WW domain
using lentiviruses or introduction of the
peptide into cells using cell-permeableevier Inc.signals blocked ERK activity in EGFR
and RAS-driven cancer cells. It also sup-
pressed growth and invasion of these
cells in vitro and inhibited the growth of
tumor xenografts in immunocompro-
mised mice. Notably, no such effects
were seen in cells when the RAS/RAF/
MEK/ERK pathway was not hyperacti-
vated, demonstrating the specificity of
this response. To assess the conse-
quences of long-term WW peptide treat-
ment, the authors used a transgenic
pancreatic cancer model driven by onco-
genic Ras and loss of Tp53. They found
that the WW peptide extended the life
of these animals with a notable lack of
toxicity when compared to animals
treated with gemcitabine.
Markedly, Jameson et al. (2013) exam-
ined the potency of WWpeptides in BRAF
drug-resistant melanoma cells. Unfortu-
nately, although BRAF drugs can achieve
impressive responses in BRAF mutant
melanoma patients, after a few months
of disease control, most patients fail on
therapy, highlighting an urgent need to
improve effectiveness of the existing
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Previewsdrugs or to develop second line treat-
ments for relapsed patients. Resistance
generally occurs through pathway reacti-
vation brought about by a variety of mech-
anisms including upregulation of RTK
signaling, acquisition of mutations in
NRAS or MEK, amplification of themutant
BRAF gene, or expression of truncated
forms of the BRAF oncoprotein. Jameson
et al. (2013) showed that the WW peptide
was effective against cell lines whose
resistance was mediated by PDGFR or
IGFR1 upregulation, mutant NRAS, or
overexpression of the MEK kinase COT.
Thus, theWWpeptide suppressed ERK
activity and blocked in vitro and in vivo
growth of cells that were addicted to the
ERK pathway (Figure 1A), establishing
that the IQGAP1 scaffold function is
essential in ERK-pathway-driven cancer
cells and validating IQGAP1 as a thera-
peutic target. What is remarkable is that
the WW peptide was relatively nontoxic.
It is known that IQGAP1 function is not
essential, because Iqgap null mice are
viable, fertile, and apparently normal,
suggesting that the scaffold function of
IQGAP within the ERK pathway is not
required in normal cells (Figure 1B). It
seems unlikely that IQGAP2 or IQGAP3
compensate for the loss of IQGAP1 scaf-
fold function in normal cells in the pres-
ence of the WW peptide, because the
WWdomain is conserved, so all three iso-
forms are likely to be equally sensitive to
disruption by the WW peptide. This sug-
gests that ERK-driven cancer cells are
particularly sensitive to both the levels
and fidelity of ERK signaling and that
IQGAP plays a key role in ensuring that
signaling is maintained at optimal levels.
Perhaps this is why these cells are sosensitive to peptides that disrupt ERK
binding, begging the question of whether
these cells would be equally sensitive to
peptides that disrupt RAF and/or MEK
binding to the IQ domain.
An exciting aspect of this study is that
the WW peptide also targets cells that
are resistant to BRAF drugs. Unfortu-
nately, the WW peptide did not synergize
with BRAF drugs to suppress the growth
of sensitive cells, but it would neverthe-
less be interesting to determine if it
delayed the onset of resistance, as
when BRAF and MEK inhibitors are
combined. It would also be interesting to
determine the mechanisms by which cells
can develop resistance to IQGAP1 drugs.
Scaffold proteins need to be expressed
within a narrow concentration range; too
little and productive signaling complexes
cannot form, but too much and the
pathway components are diluted into
incomplete and unproductive complexes.
Resistance may, therefore, arise by
manipulating the expression of the
pathway components or of IQGAP itself.
To this end, it would be interesting to
know how effective WW peptides are
when BRAF drug resistance is mediated
by the amplification of oncogenic BRAF,
expression of truncated BRAF oncopro-
teins, or mutations in MEK. It would also
be intriguing to know if IQGAP itself can
mediate resistance to BRAF drugs, and
it would be important to validate IQGAP
as a therapeutic target in BRAF mutant
colorectal cancer and thyroid carcinoma,
which typically display intrinsic resistance
to BRAF drugs (Corcoran et al., 2012;
Montero-Conde et al., 2013).
This is an important study that
validates IQGAP as a therapeutic targetCancer Cellfor first- and second-line treatments in
ERK-driven cancers. Now we need to
determine if it will prove to be a tractable
target like a kinase or a frustrating target
like RAS.REFERENCES
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